We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Celgene's former shareholders sued Bristol Myers Squibb in US court on Thursday claiming that the drugmaker failed to use its best efforts to secure FDA approval of Breyanzi (lisocabtagene maraleucel) by the end of 2020